History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report

Albina N Minlikeeva; Jo L Freudenheim; Rikki A Cannioto; Kevin H Eng; J Brian Szender; Paul Mayor; John L Etter; Daniel W Cramer; Brenda Diergaarde; Jennifer A Doherty; Thilo Dörk; Robert Edwards; Anna deFazio; Grace Friel; Marc T Goodman; Peter Hillemanns; Estrid Høgdall; Allan Jensen; Susan J Jordan; Beth Y Karlan; Susanne K Kjær; Rüdiger Klapdor; Keitaro Matsuo; Mika Mizuno; Christina M Nagle; Kunle Odunsi; Lisa Paddock; Mary Anne Rossing; Joellen M Schildkraut; Barbara Schmalfeldt; Brahm H Segal; Kristen Starbuck; Kathryn L Terry; Penelope M Webb; Emese Zsiros; Roberta B Ness; Francesmary Modugno; Elisa V Bandera; Jenny Chang-Claude; Kirsten B Moysich

doi:10.1038/bjc.2017.267

History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report

Albina N Minlikeeva, Jo L Freudenheim, Rikki A Cannioto, Kevin H Eng, J Brian Szender, Paul Mayor, John L Etter, Daniel W Cramer, Brenda Diergaarde, Jennifer A Doherty, Thilo Dörk, Robert Edwards, Anna deFazio, Grace Friel, Marc T Goodman, Peter Hillemanns, Estrid Høgdall, Allan Jensen, Susan J Jordan, Beth Y KarlanSusanne K Kjær, Rüdiger Klapdor, Keitaro Matsuo, Mika Mizuno, Christina M Nagle, Kunle Odunsi, Lisa Paddock, Mary Anne Rossing, Joellen M Schildkraut, Barbara Schmalfeldt, Brahm H Segal, Kristen Starbuck, Kathryn L Terry, Penelope M Webb, Emese Zsiros, Roberta B Ness, Francesmary Modugno, Elisa V Bandera, Jenny Chang-Claude, Kirsten B Moysich

Institut for Klinisk Medicin

9 Citationer (Scopus)

Abstract

BACKGROUND: Findings from in vitro studies suggest that increased exposure to thyroid hormones can influence progression of ovarian tumours. However, epidemiologic evidence on this topic is limited.

METHODS: We pooled data from 11 studies from the Ovarian Cancer Association Consortium. Using multivariate Cox proportional hazards models, we estimated associations between hyper- and hypothyroidism and medications prescribed for these conditions with 5-year all-cause survival among women diagnosed with invasive ovarian cancer.

RESULTS: Overall, there was a nonsignificant association with history of hyperthyroidism (n=160 cases) and mortality (HR=1.22; 95% CI=0.97-1.53). Furthermore, diagnosis of hyperthyroidism within the 5 years before ovarian cancer diagnosis was associated with an increased risk of death (HR=1.94; 95% CI=1.19-3.18). A more modest association was observed with history of hypothyroidism (n=624 cases) and mortality (HR=1.16; 95% CI=1.03-1.31). Neither duration of hypothyroidism nor use of thyroid medications was associated with survival.

CONCLUSIONS: In this large study of women with ovarian cancer, we found that recent history of hyperthyroidism and overall history of hypothyroidism were associated with worse 5-year survival.

Originalsprog	Engelsk
Tidsskrift	B J C
Vol/bind	117
Udgave nummer	7
Sider (fra-til)	1063-1069
ISSN	0007-0920
DOI	https://doi.org/10.1038/bjc.2017.267
Status	Udgivet - 26 sep. 2017

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1038/bjc.2017.267

bjc2017267.pdfForlagets udgivne version, 145 KBLicens: CC BY-NC-SA

Citationsformater

Minlikeeva, A. N., Freudenheim, J. L., Cannioto, R. A., Eng, K. H., Szender, J. B., Mayor, P., Etter, J. L., Cramer, D. W., Diergaarde, B., Doherty, J. A., Dörk, T., Edwards, R., deFazio, A., Friel, G., Goodman, M. T., Hillemanns, P., Høgdall, E., Jensen, A., Jordan, S. J., ... Moysich, K. B. (2017). History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. B J C, 117(7), 1063-1069. https://doi.org/10.1038/bjc.2017.267

Minlikeeva, AN, Freudenheim, JL, Cannioto, RA, Eng, KH, Szender, JB, Mayor, P, Etter, JL, Cramer, DW, Diergaarde, B, Doherty, JA, Dörk, T, Edwards, R, deFazio, A, Friel, G, Goodman, MT, Hillemanns, P, Høgdall, E, Jensen, A, Jordan, SJ, Karlan, BY, Kjær, SK, Klapdor, R, Matsuo, K, Mizuno, M, Nagle, CM, Odunsi, K, Paddock, L, Rossing, MA, Schildkraut, JM, Schmalfeldt, B, Segal, BH, Starbuck, K, Terry, KL, Webb, PM, Zsiros, E, Ness, RB, Modugno, F, Bandera, EV, Chang-Claude, J & Moysich, KB 2017, 'History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report', B J C, bind 117, nr. 7, s. 1063-1069. https://doi.org/10.1038/bjc.2017.267

@article{731bb3c1909b463987c948e2786a8138,

title = "History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report",

abstract = "BACKGROUND: Findings from in vitro studies suggest that increased exposure to thyroid hormones can influence progression of ovarian tumours. However, epidemiologic evidence on this topic is limited.METHODS: We pooled data from 11 studies from the Ovarian Cancer Association Consortium. Using multivariate Cox proportional hazards models, we estimated associations between hyper- and hypothyroidism and medications prescribed for these conditions with 5-year all-cause survival among women diagnosed with invasive ovarian cancer.RESULTS: Overall, there was a nonsignificant association with history of hyperthyroidism (n=160 cases) and mortality (HR=1.22; 95% CI=0.97-1.53). Furthermore, diagnosis of hyperthyroidism within the 5 years before ovarian cancer diagnosis was associated with an increased risk of death (HR=1.94; 95% CI=1.19-3.18). A more modest association was observed with history of hypothyroidism (n=624 cases) and mortality (HR=1.16; 95% CI=1.03-1.31). Neither duration of hypothyroidism nor use of thyroid medications was associated with survival.CONCLUSIONS: In this large study of women with ovarian cancer, we found that recent history of hyperthyroidism and overall history of hypothyroidism were associated with worse 5-year survival.",

keywords = "Aged, Female, Humans, Hyperthyroidism/drug therapy, Hypothyroidism/drug therapy, Middle Aged, Ovarian Neoplasms/mortality, Proportional Hazards Models, Survival Rate, Time Factors",

author = "Minlikeeva, {Albina N} and Freudenheim, {Jo L} and Cannioto, {Rikki A} and Eng, {Kevin H} and Szender, {J Brian} and Paul Mayor and Etter, {John L} and Cramer, {Daniel W} and Brenda Diergaarde and Doherty, {Jennifer A} and Thilo D{\"o}rk and Robert Edwards and Anna deFazio and Grace Friel and Goodman, {Marc T} and Peter Hillemanns and Estrid H{\o}gdall and Allan Jensen and Jordan, {Susan J} and Karlan, {Beth Y} and Kj{\ae}r, {Susanne K} and R{\"u}diger Klapdor and Keitaro Matsuo and Mika Mizuno and Nagle, {Christina M} and Kunle Odunsi and Lisa Paddock and Rossing, {Mary Anne} and Schildkraut, {Joellen M} and Barbara Schmalfeldt and Segal, {Brahm H} and Kristen Starbuck and Terry, {Kathryn L} and Webb, {Penelope M} and Emese Zsiros and Ness, {Roberta B} and Francesmary Modugno and Bandera, {Elisa V} and Jenny Chang-Claude and Moysich, {Kirsten B}",

year = "2017",

month = sep,

day = "26",

doi = "10.1038/bjc.2017.267",

language = "English",

volume = "117",

pages = "1063--1069",

journal = "The British journal of cancer. Supplement",

issn = "0007-0920",

publisher = "nature publishing group",

number = "7",

}

TY - JOUR

T1 - History of thyroid disease and survival of ovarian cancer patients

T2 - results from the Ovarian Cancer Association Consortium, a brief report

AU - Minlikeeva, Albina N

AU - Freudenheim, Jo L

AU - Cannioto, Rikki A

AU - Eng, Kevin H

AU - Szender, J Brian

AU - Mayor, Paul

AU - Etter, John L

AU - Cramer, Daniel W

AU - Diergaarde, Brenda

AU - Doherty, Jennifer A

AU - Dörk, Thilo

AU - Edwards, Robert

AU - deFazio, Anna

AU - Friel, Grace

AU - Goodman, Marc T

AU - Hillemanns, Peter

AU - Høgdall, Estrid

AU - Jensen, Allan

AU - Jordan, Susan J

AU - Karlan, Beth Y

AU - Kjær, Susanne K

AU - Klapdor, Rüdiger

AU - Matsuo, Keitaro

AU - Mizuno, Mika

AU - Nagle, Christina M

AU - Odunsi, Kunle

AU - Paddock, Lisa

AU - Rossing, Mary Anne

AU - Schildkraut, Joellen M

AU - Schmalfeldt, Barbara

AU - Segal, Brahm H

AU - Starbuck, Kristen

AU - Terry, Kathryn L

AU - Webb, Penelope M

AU - Zsiros, Emese

AU - Ness, Roberta B

AU - Modugno, Francesmary

AU - Bandera, Elisa V

AU - Chang-Claude, Jenny

AU - Moysich, Kirsten B

PY - 2017/9/26

Y1 - 2017/9/26

N2 - BACKGROUND: Findings from in vitro studies suggest that increased exposure to thyroid hormones can influence progression of ovarian tumours. However, epidemiologic evidence on this topic is limited.METHODS: We pooled data from 11 studies from the Ovarian Cancer Association Consortium. Using multivariate Cox proportional hazards models, we estimated associations between hyper- and hypothyroidism and medications prescribed for these conditions with 5-year all-cause survival among women diagnosed with invasive ovarian cancer.RESULTS: Overall, there was a nonsignificant association with history of hyperthyroidism (n=160 cases) and mortality (HR=1.22; 95% CI=0.97-1.53). Furthermore, diagnosis of hyperthyroidism within the 5 years before ovarian cancer diagnosis was associated with an increased risk of death (HR=1.94; 95% CI=1.19-3.18). A more modest association was observed with history of hypothyroidism (n=624 cases) and mortality (HR=1.16; 95% CI=1.03-1.31). Neither duration of hypothyroidism nor use of thyroid medications was associated with survival.CONCLUSIONS: In this large study of women with ovarian cancer, we found that recent history of hyperthyroidism and overall history of hypothyroidism were associated with worse 5-year survival.

AB - BACKGROUND: Findings from in vitro studies suggest that increased exposure to thyroid hormones can influence progression of ovarian tumours. However, epidemiologic evidence on this topic is limited.METHODS: We pooled data from 11 studies from the Ovarian Cancer Association Consortium. Using multivariate Cox proportional hazards models, we estimated associations between hyper- and hypothyroidism and medications prescribed for these conditions with 5-year all-cause survival among women diagnosed with invasive ovarian cancer.RESULTS: Overall, there was a nonsignificant association with history of hyperthyroidism (n=160 cases) and mortality (HR=1.22; 95% CI=0.97-1.53). Furthermore, diagnosis of hyperthyroidism within the 5 years before ovarian cancer diagnosis was associated with an increased risk of death (HR=1.94; 95% CI=1.19-3.18). A more modest association was observed with history of hypothyroidism (n=624 cases) and mortality (HR=1.16; 95% CI=1.03-1.31). Neither duration of hypothyroidism nor use of thyroid medications was associated with survival.CONCLUSIONS: In this large study of women with ovarian cancer, we found that recent history of hyperthyroidism and overall history of hypothyroidism were associated with worse 5-year survival.

KW - Aged

KW - Female

KW - Humans

KW - Hyperthyroidism/drug therapy

KW - Hypothyroidism/drug therapy

KW - Middle Aged

KW - Ovarian Neoplasms/mortality

KW - Proportional Hazards Models

KW - Survival Rate

KW - Time Factors

U2 - 10.1038/bjc.2017.267

DO - 10.1038/bjc.2017.267

M3 - Letter

C2 - 28817835

SN - 0007-0920

VL - 117

SP - 1063

EP - 1069

JO - The British journal of cancer. Supplement

JF - The British journal of cancer. Supplement

IS - 7

ER -

History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater